Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.

Prostate cancer is the most common cancer diagnosis in men in the United States and a leading cause of cancer-related morbidity and mortality.1 It can exist along a wide spectrum of aggressiveness and severity, from indolent, very low risk, localized prostate cancer to lifethreatening, very high risk, metastatic prostate cancer. For a newly diagnosed patient in a given clinical state, especially early in the disease, the spectrum of appropriate therapeutic options may range from no intervention to multimodality therapy. Accurate assessment of the extent of disease (e.g., metastatic vs. localized prostate cancer) is essential for guiding treatment decisions. Decision making for the clinical use of imaging and for the development of new imaging technology can both be organized by the framing principles outlined in Prostate Cancer Working Group 3.2

Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2021 Sep 30 [Epub]

Hossein Jadvar, Jeremie Calais, Stefano Fanti, Felix Feng, Kirsten L Greene, James L Gulley, Michael Hofman, Bridget F Koontz, Daniel W Lin, Michael J Morris, Steve P Rowe, Trevor J Royce, Simpa Salami, Bital Savir-Baruch, Sandy Srinivas, Thomas A Hope

Department of Radiology, University of Southern California, Los Angeles, California; ., Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California., University of Bologna, Bologna, Italy., Department of Radiation Oncology, University of California, San Francisco, California., Department of Urology, University of Virginia, Charlottesville, Virginia., National Institutes of Health, Bethesda, Maryland., Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria Australia., Department of Radiation Oncology, Duke University, Durham, North Carolina., Department of Urology, University of Washington, Seattle, Washington., Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York., Department of Radiological Sciences, Johns Hopkins University, Baltimore, Maryland., Department of Radiation Oncology, University of North Carolina, Chapel Hill, North Carolina., Department of Urology, University of Michigan, Ann Arbor, Michigan., Department of Radiology, Loyola University, Maywood, Illinois., Department of Medicine (Oncology), Stanford University, California; and., Department of Radiology and Biomedical Imaging, University of California, San Francisco, California.